Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Cohen

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 22, 2025
Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's diseaseJeffrey Cummings, Sharon Cohen, Jennifer Murphy, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacyJaren W Landen, Sharon Cohen, Clare B Billing, et al.
The New England Journal of Medicine|November 30, 2022
Lecanemab in Early Alzheimer's DiseaseChristopher H van Dyck, Chad J Swanson, Paul Aisen, et al.
Drugs|September 28, 2025
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 TrialSusan Abushakra, Aidan Power, David Watson, et al.
JAMA Neurology|November 26, 2019
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical TrialsAlette M Wessels, Pierre N Tariot, Jennifer A Zimmer, et al.
CNS Drugs|December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional TrialsSusan Abushakra, P Murali Doraiswamy, John A Hey, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trialStephen Macfarlane, Timo Grimmer, Ken Teo, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 22, 2025
Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's diseaseJeffrey Cummings, Sharon Cohen, Jennifer Murphy, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacyJaren W Landen, Sharon Cohen, Clare B Billing, et al.
The New England Journal of Medicine|November 30, 2022
Lecanemab in Early Alzheimer's DiseaseChristopher H van Dyck, Chad J Swanson, Paul Aisen, et al.
Drugs|September 28, 2025
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 TrialSusan Abushakra, Aidan Power, David Watson, et al.
JAMA Neurology|November 26, 2019
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical TrialsAlette M Wessels, Pierre N Tariot, Jennifer A Zimmer, et al.
CNS Drugs|December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional TrialsSusan Abushakra, P Murali Doraiswamy, John A Hey, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trialStephen Macfarlane, Timo Grimmer, Ken Teo, et al.
Pageof 6